26,33 $
2,12 % vorgestern
Nasdaq, 25. Juli, 22:14 Uhr
ISIN
BMG5269C1010
Symbol
KNSA
Berichte

Kiniksa Pharmaceuticals Ltd. Class A Aktie News

Neutral
GlobeNewsWire
3 Tage alt
LONDON, July 24, 2025 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 financial results and recent portfolio execution.
Positiv
The Motley Fool
24 Tage alt
Explore the exciting world of Kiniksa Pharmaceuticals (KNSA 0.99%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Positiv
Investors Business Daily
26 Tage alt
Biotech stock Kiniksa soared after first-quarter results on April 29. Shares are near a buy point of 28.15.
Positiv
Seeking Alpha
etwa ein Monat alt
Kiniksa Pharmaceuticals has delivered strong share price performance this year thanks to a strong start to the year for Arcalyst. Medicare redesign with improved patient affordability has boosted Arcalyst's sales and 2025 outlook. I expect a beat-and-raise 2025 with Arcalyst net sales reaching or exceeding $620 million.
Neutral
GlobeNewsWire
etwa 2 Monate alt
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – KPL-387 Phase 1 single ascending dose data support profile for monthly dosing – – Presentation and webcast at Jefferies 2025 Global Healthcare Conference scheduled for 12:50 pm ET today–
Neutral
GlobeNewsWire
etwa 2 Monate alt
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the following investor conferences in June:
Positiv
Seeking Alpha
3 Monate alt
Kiniksa Pharmaceuticals posted strong Q1 results last week, beating expectations and raising 2025 ARCALYST net sales guidance to $590-$605 million, up from $560-$580 million. Analyst firms are optimistic, with firms like Goldman Sachs, Wedbush, and Jefferies assigning Buy ratings and price targets ranging from $32 to $45 on the shares. Kiniksa also has a solid balance sheet with nearly $270 mil...
Neutral
GlobeNewsWire
3 Monate alt
– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed –

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen